Highest-materiality recent filing
Enanta Q3 FY26 net loss $19.5M; cash $211.5M; RSV and immunology programs on track
Revenue $14.4M from MAVYRET royalties, down from $18.3M YoY; net loss $19.5M ($0.67/sh) vs $18.3M ($0.85/sh).
Enanta loses Federal Circuit appeal; Paxlovid patent claims invalidated
Federal Circuit affirmed Dec 2024 summary judgment, ruling claims of U.S. Patent No. 11,358,953 invalid.
Registrational Phase 2b/3 trial in high-risk adults (≥75 yrs, COPD, CHF) to start 4Q 2026; Phase 2b topline data expected 2027.
Revenue of $18.6M from AbbVie royalties, up 9% vs $17.0M YoY; net loss narrowed to $11.9M from $22.3M.
Net loss $18.7M ($0.87 loss per share) vs $28.8M loss ($1.36/sh) in Q4 2024.
6,500,000 shares offered at $10.00 per share; underwriters have 30-day option for 975,000 more shares.
Zelicapavir shows 6.7-day symptom resolution improvement in high-risk RSV adults
6.7-day faster complete resolution of all 13 RSV symptoms in HR3 population (COPD/CHF/age≥75); 7.2-day improvement in total RiiQ.
Enanta reports positive Phase 2b topline data for zelicapavir in high-risk RSV adults
Phase 2b study of zelicapavir (formerly EDP-938) met primary endpoint in high-risk adults with RSV.
Enanta sues Pfizer in EU UPC for Paxlovid patent infringement
Filed suit in Unified Patent Court (action 35071/2025) alleging Pfizer's Paxlovid infringes European Patent EP 4 051 265.
Enanta Q3 net loss $18.3M ($0.85/sh); RSV topline data due Sept
Revenue of $18.3M from AbbVie royalties; net loss narrowed vs $22.7M Q3 2024.
Enanta Q2 net loss narrows to $22.6M; RSV study enrollment target met
Revenue $14.9M, down 13% YoY from $17.1M; net loss $22.6M ($1.06 loss per share) vs $31.2M ($1.47) in prior year.
Enanta Q1 net loss narrows to $22.3M; RSV Phase 2 topline data due Q3 2025
Net loss $22.3M (-$1.05/sh) vs loss $33.4M (-$1.58/sh) YoY; revenue $17M from MAVYRET royalties.
Part 2 primary endpoint: 1.4 log viral load decline at Day 5 vs placebo (n=34 zelicapavir, n=10 placebo).
Enanta reports FY2024 revenue $67.6M, net loss $116M; RSV & immunology pipelines advance
Q4 revenue $14.6M (down 23% YoY); full-year $67.6M vs $79.2M due to lower MAVYRET royalties.
Enanta Q2 net loss $31.2M; cash $300.3M; RSV data readouts expected in 2H 2024
Fiscal Q2 2024 revenue $17.1M (AbbVie HCV royalty); net loss $31.2M ($1.47 loss/share) vs $37.7M loss a year ago.
Enanta Q1 revenue $18M, net loss $33.4M; RSV data expected Q3 2024
Revenue $18.0M (down from $23.6M YoY) from AbbVie's MAVYRET royalties; net loss $33.4M ($1.58/share) vs $29.0M loss YoY.
Enanta reports Q4 net loss $28.1M; initiates EDP-323 Phase 2a RSV study
Q4 revenue $18.9M (down from $20.3M YoY); FY revenue $79.2M (down from $86.2M).
Enanta Q3 loss $1.86/diluted share; revenue $18.9M; positive Phase 1 RSV data
Net loss $39.1M ($1.86/diluted) vs. $31.7M ($1.53) in prior-year Q3; revenue $18.9M down from $19.5M.
Enanta EDP-235 shows 0.8-1.0 log viral load decline in Phase 2 COVID-19 trial subset
In nucleocapsid-negative patients, 400mg EDP-235 showed 0.8 log viral load decline vs placebo at Day 5.
Enanta Q2 net loss widens to $37.7M; reports positive Phase 2 COVID-19 data, $200M royalty sale
Net loss $37.7M ($1.79 loss/diluted share) vs $33.6M loss ($1.63) YoY; revenue $17.8M from HCV royalties.
Enanta sells 54.5% of MAVYRET royalties to OMERS for $200M; non-dilutive funding
Sold 54.5% of future royalty payments on MAVYRET/MAVIRET worldwide sales to OMERS Life Sciences for $200M.
Revenue $23.6M, down from $27.6M YoY, primarily from MAVYRET royalties.
Enanta reports Q4 net loss $26.3M, revenue $20.3M; initiates Phase 2 COVID-19 trial
Q4 royalty revenue $20.3M (down 14% YoY); full year revenue $86.2M vs $97.1M.
Enanta Pharmaceuticals enters ATM agreement with Jefferies for up to $100M common stock offering
Open Market Sale Agreement with Jefferies LLC allows at-the-market sales of up to $100M in common stock.
Enanta posts Q3 loss of $31.7M; sues Pfizer for Paxlovid patent infringement
Net loss of $31.7M ($1.53 diluted loss per share) vs $24.0M loss ($1.19) in prior year; revenue $19.5M from AbbVie royalties, down from $21.6M.
Enanta sues Pfizer for patent infringement over Paxlovid, seeks damages only
Filed suit against Pfizer in U.S. District Court for Massachusetts over U.S. Patent No. 11,358,953 covering coronavirus protease inhibitors.
Enanta signs 10-year lease for ~73k sq ft HQ expansion in Watertown, MA; amends existing leases
New lease with ARE-MA Region No. 75 for ~73,000 sq ft at Arsenal on the Charles; 10-year term starting June 2024.
Enanta reports Q2 net loss of $33.6M; revenue down to $18.7M on lower HCV royalties
Net loss of $33.6M ($1.63/share) vs. loss of $22.0M ($1.09/share) last year.
Enanta Q1 net loss $30.1M; plans to start EDP-235 Phase 1 this month
Net loss of $30.1M ($1.48 per diluted share) vs $8.3M loss in prior-year quarter.
Q4 revenue $23.6M (flat YoY); net loss $24.6M ($1.22 loss per diluted share) vs $29.3M loss a year ago.
Enanta reports Q3 fiscal 2021 net loss of $24.0M; nominates COVID-19 protease inhibitor EDP-235
Royalty revenue $21.6M from AbbVie's HCV regimen; net loss $24.0M ($1.19/sh) vs loss $14.3M ($0.71/sh) year ago.
On December 19, 2023, Nathaniel S. Gardiner, age 70, Senior Vice President and General Counsel of Enanta Pharmaceuticals, Inc., announced his intention to retire on or before March 31, 2024.
The Board of Directors of Enanta Pharmaceuticals, Inc. has elected Yujiro S. Hata to serve as an independent director of the company in the class of directors whose term expires at Enanta’s 2024 annual meeting of stockholders.
On July 14, 2021, Nathalie Adda, M.D., Senior Vice President, Chief Medical Officer of Enanta Pharmaceuticals, Inc. (“Enanta”) announced her retirement effective February 28, 2022 (the “Effective Date”).
Max materiality 0.80 · Median 0.65 · Most common event earnings